US Stock MarketDetailed Quotes

MRVI Maravai LifeSciences

Watchlist
  • 2.370
  • +0.070+3.04%
Close Mar 26 16:00 ET
  • 2.370
  • 0.0000.00%
Post 20:01 ET
340.45MMarket Cap-2.26P/E (TTM)

About Maravai LifeSciences Company

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Company Profile

SymbolMRVI
Company NameMaravai LifeSciences
Listing DateNov 20, 2020
Issue Price27.00
Founded2014
CEOMr. William E. Martin, III
MarketNASDAQ
Employees570
Fiscal Year Ends12-31
Address10770 Wateridge Circle,Suite 200
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121
Phone1-858-546-0004

Company Executives

  • Name
  • Position
  • Salary
  • William E. Martin, III
  • Chief Executive Officer and Director
  • 2.30M
  • Kevin Herde
  • Chief Financial Officer and Principal Accounting Officer
  • 2.79M
  • Dr. Peter M. Leddy, PhD
  • Chief Administrative Officer
  • 2.83M
  • Rebecca Buzzeo
  • Executive Vice President and Chief Commercial Officer
  • --
  • Christine Dolan
  • Executive Vice President and General Manager, Cygnus Technologies
  • 2.26M
  • Robert Andrew Eckert
  • Chairman of the Board
  • --
  • Luke Marker
  • Director
  • 360.48K
  • Constantine S. Mihas
  • Director
  • 370.48K
  • Sean L. Cunningham
  • Director
  • 367.98K
  • Benjamin Daverman
  • Director
  • 360.48K
  • Gregory T. Lucier
  • Independent Director
  • 360.48K
  • Dr. John A. DeFord, PhD
  • Independent Director
  • 435.03K
  • Dr. Jessica Hopfield, PhD
  • Independent Director
  • 387.98K
  • Susannah Gray, M.B.A.
  • Independent Director
  • 395.48K
  • Dr. Murali K. Prahalad, PhD
  • Independent Director
  • 367.98K
  • Kurt Oreshack
  • General Counsel and Secretary
  • --

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More